SOURCE: Entest BioMedical Inc.

February 03, 2011 10:14 ET

Entest BioMedical Inc. Enters Collaboration With RenovoCyte LLC and Medistem Inc. in Developing Stem Cell Therapy for Treating Canine Hip Dysplasia

SAN DIEGO, CA--(Marketwire - February 3, 2011) - Entest BioMedical Inc. (OTCBB: ENTB)

  • One out of every four dogs will get hip dysplasia
  • Entest and RenovoCyte are researching the use of Medistem's Canine Endometrial Regenerative Cells (CERCs) as part of a treatment for canine hip dysplasia 
  • Entest's McDonald Animal Hospital to serve as clinical base for studies

Entest BioMedical Inc. (OTCBB: ENTB) announced today the initiation of a collaboration with RenovoCyte LLC and Medistem Inc. to explore the development of a stem cell therapy for treating hip dysplasia in dogs. Hip dysplasia is a painful, crippling disease that causes a dog's hip to weaken, deteriorate and become arthritic. This disease impacts one out of every four dogs. The condition can be extremely debilitating causing severe pain and immobility.

Entest's Chairman & CEO, David Koos, stated, "Our Company is extremely excited about clinically applying Medistem's Canine Endometrial Regenerative Cells (CERCs) and RenovoCyte's Investigational New Animal Drug (INAD) protocols at our McDonald Animal Hospital. Entest views this collaboration as a major step in developing veterinary therapeutics that increase the quality of life for our pets." 

Both RenovoCyte's CEO Dr. Erik Woods and Medistem's Chairman Vladimir Bogin, M.D., stated they anticipate these CERCs will reduce the inflammation and the degenerative nature of hip dysplasia in dogs.

A spokesperson for Entest noted that once efficacy is demonstrated in treating hip dysplasia, the door will be wide open for our collaboration to expand its focus to treating other veterinary conditions that are lacking a good treatment model.

About Entest BioMedical Inc.:

Entest BioMedical Inc. (OTCBB: ENTB) is a biotechnology company focused on the development of regenerative and immunological therapies for veterinary applications. The Company is specifically interested in veterinary therapies that harness the animal's own reparative and immunological mechanisms. Entest's products include an immuno-therapeutic cancer vaccine for canines (ImenVax™). ImenVax™ utilizes an encapsulation device as the vaccine delivery system and requires a simple implant procedure. Additionally, the Company is interested in acquiring veterinary hospitals as both a source of near term revenue and as a distribution channel for its veterinary therapies and treatments. As part of this mission, Entest purchased the McDonald Animal Hospital on January 4, 2011, which serves to both generate revenue and provide the initial part of Entest's distribution channel.


This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

Contact Information